Eyewash Station Additive Concentrate Liquid
NDC Package 65785-034-01
Package Information
Eyewash Station Additive Concentrate (chlorhexidine gluconate and propylene glycol) liquids is wear protective eyewear and glovesclean potable eyewash station and rinse with potable waterpartially fill station with potable waterremove tamper evident seal and cap of bottleadd entire contents of the bottle to the eyewash station containerfill the station to the manufacturer's required leveldate and initial inspection tagstation should be cleaned and refilled every 120 days when using this productin advance of emergency, add the concentrate to potable water to have a solution available. This formulation utilizes a liquid delivery system. Marketed by Niagara Pharmaceuticals Inc., this product is identified by NDC 65785-034 and is authorized under FDA application M018.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 65785 - Niagara Pharmaceuticals Inc.
- 65785-034 - Eyewash Station Additive Concentrate
- 65785-034-01 - .236 L in 1 BOTTLE, UNIT-DOSE
- 65785-034 - Eyewash Station Additive Concentrate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 65785-034-01 identifies a specific commercial package of .236 l in 1 bottle, unit-dose of Eyewash Station Additive Concentrate, a human over the counter drug labeled by Niagara Pharmaceuticals Inc.. This liquid is formulated for ophthalmic use and contains chlorhexidine gluconate; propylene glycol as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Niagara Pharmaceuticals Inc. on November 15, 2011. The current certification is valid through December 31, 2026.
How is this Niagara Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 65785003401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.